Retagliptin

Retagliptin
Identifiers
	IUPAC name Methyl 7-[(3R)-3-amino-4-(2,4,5-trifluorophenyl)butanoyl]-3-(trifluoromethyl)-6,8-dihydro-5H-imidazo[1,5-a]pyrazine-1-carboxylate;
CAS Number	1174122-54-3 ;
PubChem CID	44193830 ;
DrugBank	DB14898 ;
ChemSpider	57583801 ;
UNII	328C4R3P9L ;
ChEMBL	ChEMBL4297435 ;
Chemical and physical data
Formula	C19H18F6N4O3
Molar mass	464.368 g·mol−1
3D model (JSmol)	Interactive image ;
	SMILES COC(=O)C1=C2CN(CCN2C(=N1)C(F)(F)F)C(=O)C[C@@H](CC3=CC(=C(C=C3F)F)F)N;
	InChI InChI=1S/C19H18F6N4O3/c1-32-17(31)16-14-8-28(2-3-29(14)18(27-16)19(23,24)25)15(30)6-10(26)4-9-5-12(21)13(22)7-11(9)20/h5,7,10H,2-4,6,8,26H2,1H3/t10-/m1/s1; Key:WIIAMRXFUJLYEF-SNVBAGLBSA-N;

Last updated August 26, 2025

Retagliptin is a DPP-4 inhibitor studied for the treatment of type 2 diabetes.^[1]^[2]^[3]

In 2023, it was approved in China by the National Medical Products Administration for blood glucose control for adult patients with type 2 diabetes.^[4]

References

↑ Meng, Xiangjun; Cai, Lanlan; Ren, Tianming; Sun, Dong; Gu, Jingkai (2018). "Simultaneous quantitative analysis of retagliptin and its main active metabolite in human multiple matrices by liquid chromatography tandem mass spectrometry" . Analytical Methods. 10 (18): 2108–2114. doi:10.1039/C8AY00040A. ISSN 1759-9679.
↑ Hu, Chao; Zheng, Jing; Miao, Jia; Liu, Fang; Hu, Ting-Ting; Gu, Jing-Kai; Shu, Shi-Qing; Wang, Ying; Zhu, Xiao-Hong; Liang, Mao-Zhi (2018). "[Pharmacokinetics of Phosphate Retagliptin Tabletin in Patients with Renal Dysfunction]". Sichuan da Xue Xue Bao. Yi Xue Ban = Journal of Sichuan University. Medical Science Edition. 49 (1): 74–80. ISSN 1672-173X. PMID 29737094.
↑ Cahn, Avivit; Cernea, Simona; Raz, Itamar (2016). "An update on DPP-4 inhibitors in the management of type 2 diabetes". Expert Opinion on Emerging Drugs. 21 (4): 409–419. doi:10.1080/14728214.2016.1257608. PMID 27809608. S2CID 45825587.
↑ "Retagliptin Phosphate Tablets Approved for Marketing by NMPA". National Medical Products Administration. 2023-06-28.

This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.

[1] Meng, Xiangjun; Cai, Lanlan; Ren, Tianming; Sun, Dong; Gu, Jingkai (2018). "Simultaneous quantitative analysis of retagliptin and its main active metabolite in human multiple matrices by liquid chromatography tandem mass spectrometry" . Analytical Methods. 10 (18): 2108–2114. doi:10.1039/C8AY00040A. ISSN 1759-9679.

[2] Hu, Chao; Zheng, Jing; Miao, Jia; Liu, Fang; Hu, Ting-Ting; Gu, Jing-Kai; Shu, Shi-Qing; Wang, Ying; Zhu, Xiao-Hong; Liang, Mao-Zhi (2018). "[Pharmacokinetics of Phosphate Retagliptin Tabletin in Patients with Renal Dysfunction]". Sichuan da Xue Xue Bao. Yi Xue Ban = Journal of Sichuan University. Medical Science Edition. 49 (1): 74–80. ISSN 1672-173X. PMID 29737094.

[3] Cahn, Avivit; Cernea, Simona; Raz, Itamar (2016). "An update on DPP-4 inhibitors in the management of type 2 diabetes". Expert Opinion on Emerging Drugs. 21 (4): 409–419. doi:10.1080/14728214.2016.1257608. PMID 27809608. S2CID 45825587.

[4] "Retagliptin Phosphate Tablets Approved for Marketing by NMPA". National Medical Products Administration. 2023-06-28.

[1]

[2]

[3]

[4]

Identifiers

IUPAC name Methyl 7-[(3R)-3-amino-4-(2,4,5-trifluorophenyl)butanoyl]-3-(trifluoromethyl)-6,8-dihydro-5H-imidazo[1,5-a]pyrazine-1-carboxylate
CAS Number	1174122-54-3
PubChem CID	44193830
DrugBank	DB14898
ChemSpider	57583801
UNII	328C4R3P9L
ChEMBL	ChEMBL4297435
Chemical and physical data
Formula	C₁₉H₁₈F₆N₄O₃
Molar mass	464.368 g·mol⁻¹
3D model (JSmol)	Interactive image
SMILES COC(=O)C1=C2CN(CCN2C(=N1)C(F)(F)F)C(=O)C[C@@H](CC3=CC(=C(C=C3F)F)F)N
InChI InChI=1S/C19H18F6N4O3/c1-32-17(31)16-14-8-28(2-3-29(14)18(27-16)19(23,24)25)15(30)6-10(26)4-9-5-12(21)13(22)7-11(9)20/h5,7,10H,2-4,6,8,26H2,1H3/t10-/m1/s1 Key:WIIAMRXFUJLYEF-SNVBAGLBSA-N